ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

advanced pharmaceuticals pty ltd - 46206 - skin moisturizing/barrier dressing - a protective barrier cream for the treatment and prevention of nappy rash. soothes protects and relieves the symptoms of chafed skin, windburn, mild eczema, mild dermatitis, minor skin irritations, dry, cracked lips & pressure sores. assists with wound healing & tissue repair. moisturising skin protectant.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

advanced pharmaceuticals pty ltd - 42345 - dental solution, mouthwash - a solution in the form of a mouthwash used for cleansing and aiding oral hygiene. contains chlorhexidine gluconate 0.2%. acts to protect the oral cavity and health of teeth and gums. use of this product: helps reduce plaque; provide relief from gingivitis; helps to prevent and reduce bad breath; provide relief from mouth ulcers; maintain oral hygiene.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

advanced pharmaceuticals pty ltd - 46206 - skin moisturizing/barrier dressing - paw paw ointment soothes, protects & relieves the symptoms of chapped dry lips, nappy rash, chafed skin, mild eczema, mild sunburn, insect bites & minor skin irritations. protects, soothes and restores dry or irritated skin

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

advanced pharmaceuticals pty ltd - 42345 - dental solution, mouthwash - a mouthwash used short term for cleansing and aiding oral hygiene. helps to prevent and reduce bad breath. may relieve the discomfort of mouth ulcers.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

petrus pharmaceuticals pty ltd - 33587 - general-body orifice lubricant, non-sterile - for personal, surgical and gynaecological lubrication.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

padagis israel pharmaceuticals ltd - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - ciclopirox 1 g in 100 ml - ciclopirox shampoo, 1% is indicated for the topical treatment of seborrheic dermatitis of the scalp in adults. none. teratogenic effects: pregnancy category b there are no adequate or well-controlled studies in pregnant women. therefore, ciclopirox shampoo, 1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. oral embryofetal developmental studies were conducted in mice, rats, rabbits and monkeys. ciclopirox or ciclopirox olamine was orally administered during the period of organogenesis. no maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 77, 125, 80 and 38.5 mg/kg/day ciclopirox in mice, rats, rabbits and monkeys, respectively (approximately 13, 42, 54 and 26 times the maximum recommended human dose based on body surface area comparisons, respectively). dermal embryofetal developmental studies were conducted in rats and rabbits with ciclopirox olamine dissolved in peg 400. ciclopirox olamine was topically administered during the period of organogenesis. no maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 92 mg/kg/day and 77 mg/kg/day ciclopirox in rats and rabbits, respectively (approximately 31 and 54 times the maximum recommended human dose based on body surface area comparisons, respectively). it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when ciclopirox shampoo, 1% is administered to a nursing woman. no clinical trials have been conducted in subjects younger than 16 years. in clinical trials, the safety and tolerability of ciclopirox shampoo, 1% in the population 65 years and older was comparable to that of younger subjects. results of the efficacy analysis in those subjects 65 years and older showed effectiveness in 25 of 85 (29%) subjects treated with ciclopirox shampoo, 1%, and in 15 of 61 (25%) subjects treated with the vehicle; due to the small sample size, a statistically significant difference was not demonstrated. other reported clinical experience has not identified differences in responses between the elderly and younger subjects, but greater sensitivity to adverse effects in some older individuals cannot be ruled out.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

sun pharmaceuticals industries australia pty ltd - gemcitabine hydrochloride -

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - tranexamic acid, quantity: 500 mg - injection, solution - excipient ingredients: water for injections - adults for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty. paediatrics for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - tranexamic acid, quantity: 1000 mg - injection, solution - excipient ingredients: water for injections - adults for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty. paediatrics for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - gemcitabine hydrochloride, quantity: 2277.2 mg (equivalent: gemcitabine, qty 2000 mg) - injection, concentrated - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic non-small cell lung cancer. gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic adenocarcinoma of the pancreas. gemcitabine is also indicated for patients with 5-fu refractory pancreatic cancer. gemcitabine kabi, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. gemcitabine kabi, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. gemcitabine kabi, in combinatin with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.